These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 924516)
21. Genetic and cellular basis of anti-DNA antibody synthesis in systemic lupus erythematosus of New Zealand mice. Shirai T; Hirose S; Sekigawa I; Okada T; Sato H J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():11-20. PubMed ID: 3497267 [TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Ryffel B; Car BD; Gunn H; Roman D; Hiestand P; Mihatsch MJ Am J Pathol; 1994 May; 144(5):927-37. PubMed ID: 8178944 [TBL] [Abstract][Full Text] [Related]
23. Anxiety behavior, exploratory behavior, and activity in NZB x NZW F1 hybrid mice: role of genotype and autoimmune disease progression. Schrott LM; Crnic LS Brain Behav Immun; 1996 Sep; 10(3):260-74. PubMed ID: 8954598 [TBL] [Abstract][Full Text] [Related]
24. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Bahjat FR; Pine PR; Reitsma A; Cassafer G; Baluom M; Grillo S; Chang B; Zhao FF; Payan DG; Grossbard EB; Daikh DI Arthritis Rheum; 2008 May; 58(5):1433-44. PubMed ID: 18438845 [TBL] [Abstract][Full Text] [Related]
25. Establishment of a nucleoside-specific suppressor T cell line from SLE prone (NZB/NZW)F1 mice. Naiki M; Imai Y; Osawa T J Immunol; 1985 Aug; 135(2):1080-5. PubMed ID: 2409137 [TBL] [Abstract][Full Text] [Related]
26. Genetic control of the spontaneous activation of CD4+ Th cells in systemic lupus erythematosus-prone (NZB x NZW) F1 mice. Fujii T; Iida Y; Yomogida M; Ikeda K; Haga T; Jikumaru Y; Ninami M; Nishimura N; Kodera Y; Inada Y; Shirai T; Hirose S; Nishimura H Genes Immun; 2006 Dec; 7(8):647-54. PubMed ID: 17024131 [TBL] [Abstract][Full Text] [Related]
27. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Dong L; Ito S; Ishii KJ; Klinman DM Arthritis Rheum; 2005 Feb; 52(2):651-8. PubMed ID: 15692999 [TBL] [Abstract][Full Text] [Related]
28. [Therapy of systemic lupus erythematosus--studies using disease models. 1. The effect of MHC on lupus nephritis in (NZB x NZW)F1--a therapeutic suggestion]. Sato H; Hirose S; Shirai S Nihon Rinsho; 1984 Dec; 42(12):2791-5. PubMed ID: 6530763 [No Abstract] [Full Text] [Related]
29. Acceleration of glomerulonephritis in NZB x NZW mice by early immunization with DNA and injection of bacterial lipopolysaccharide. Experimental approach to the treatment of lupus nephritis by use of the accelerated model of NZB x NZW mouse disease. Fournie GJ; Minh MG; Mignon-Conte MA; Hass S; Lambert PH; Conte JJ J Clin Lab Immunol; 1980 Sep; 4(2):103-6. PubMed ID: 7441709 [TBL] [Abstract][Full Text] [Related]
30. The contribution of I-Abm12 to phenotypic and functional alterations among T-cell subsets in NZB mice. Naiki M; Yoshida SH; Watanabe Y; Izui S; Ansari AA; Gershwin ME J Autoimmun; 1993 Apr; 6(2):131-43. PubMed ID: 8388689 [TBL] [Abstract][Full Text] [Related]
31. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice. Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860 [TBL] [Abstract][Full Text] [Related]
32. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. Wofsy D; Seaman WE J Immunol; 1987 May; 138(10):3247-53. PubMed ID: 3106478 [TBL] [Abstract][Full Text] [Related]
33. Late treatment of murine lupus erythematosus with dactinomycin (actinomycin D). I. Course and longevity. Gabrielsen AE; Olsen CT Clin Exp Immunol; 1979 Jan; 35(1):33-5. PubMed ID: 428145 [TBL] [Abstract][Full Text] [Related]
34. Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone. Walker SE; Anver MR Clin Exp Immunol; 1978 Sep; 33(3):453-62. PubMed ID: 737897 [TBL] [Abstract][Full Text] [Related]
35. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity in kidney tissue from NZB/NZW F1 hybrid mice. Casey ML; Hurd ER; Gilliam JN; MacDonald PC; Johnston JM Immunology; 1982 Jan; 45(1):23-6. PubMed ID: 7056565 [TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor levels in a murine model of systemic lupus erythematosus. Athreya BH; Moore WC; Wadsworth SA; Gupta C; Goldman AS Clin Exp Rheumatol; 1989; 7(6):589-93. PubMed ID: 2612080 [TBL] [Abstract][Full Text] [Related]
37. The oncogenic effect of immunosuppressive (cytotoxic) agents in (NZB X NZW) mice. I. Long-term treatment with azathioprine and ifosfamide. Mitrou PS; Fischer M; Mitrou G; Röttger P; Holtz G Arzneimittelforschung; 1979; 29(3):483-8. PubMed ID: 314806 [TBL] [Abstract][Full Text] [Related]
38. Reversal of nzb/nzw disease with total lymphoid irradiation. Kotzin BL; Strober S J Exp Med; 1979 Aug; 150(2):371-8. PubMed ID: 313431 [TBL] [Abstract][Full Text] [Related]
39. Unilateral nephrectomy: effect on survival in NZB/NZW mice. Beyer MM; Steinberg AD; Nicastri AD; Friedman EA Science; 1977 Nov; 198(4316):511-3. PubMed ID: 143718 [TBL] [Abstract][Full Text] [Related]